Myelofibrosis is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Myelofibrosis have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Myelofibrosis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Myelofibrosis overview
Myelofibrosis is a rare bone marrow disorder where abnormal cells cause fibrous tissue buildup, impairing blood cell production. It’s a type of myeloproliferative neoplasm, leading to an enlarged spleen, anemia, fatigue, and increased infection risk. JAK2, MPL, or CALR mutations often underlie this condition. Diagnosis involves blood tests, bone marrow biopsy, and imaging. Treatment aims to manage symptoms and might involve medications, blood transfusions, targeted therapies, or stem cell transplantation in severe cases. Myelofibrosis is chronic and variable; management focuses on improving quality of life and addressing complications through personalized approaches and regular monitoring.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Myelofibrosis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
